231 related articles for article (PubMed ID: 24927176)
1. TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.
Jang JY; Kim SJ; Cho EK; Jeong SW; Park EJ; Lee WC; Lee SH; Kim SG; Kim YS; Kim HS; Kim BS; Lin W; Chung RT
PLoS One; 2014; 9(6):e98171. PubMed ID: 24927176
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus sensitizes host cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 via a MEK1-dependent pathway.
Deng Z; Yan H; Hu J; Zhang S; Peng P; Liu Q; Guo D
PLoS One; 2012; 7(5):e37700. PubMed ID: 22662193
[TBL] [Abstract][Full Text] [Related]
3. HIV infection increases HCV-induced hepatocyte apoptosis.
Jang JY; Shao RX; Lin W; Weinberg E; Chung WJ; Tsai WL; Zhao H; Goto K; Zhang L; Mendez-Navarro J; Jilg N; Peng LF; Brockman MA; Chung RT
J Hepatol; 2011 Apr; 54(4):612-20. PubMed ID: 21146890
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway.
Chou AH; Tsai HF; Wu YY; Hu CY; Hwang LH; Hsu PI; Hsu PN
J Immunol; 2005 Feb; 174(4):2160-6. PubMed ID: 15699147
[TBL] [Abstract][Full Text] [Related]
5. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
[TBL] [Abstract][Full Text] [Related]
6. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
7. Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.
Bertram H; Nerlich A; Omlor G; Geiger F; Zimmermann G; Fellenberg J
Mod Pathol; 2009 Jul; 22(7):895-905. PubMed ID: 19305384
[TBL] [Abstract][Full Text] [Related]
8. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
9. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
10. 6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5.
Wang LL; Li RT; Zang ZH; Song YX; Zhang YZ; Zhang TF; Wang FZ; Hao GP; Cao L
Med Oncol; 2023 Aug; 40(9):266. PubMed ID: 37566135
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin.
Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
Med Oncol; 2015 Apr; 32(4):133. PubMed ID: 25796504
[TBL] [Abstract][Full Text] [Related]
12. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
14. CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells.
Kim EY; Ryu JH; Kim AK
Int J Oncol; 2013 Oct; 43(4):1291-300. PubMed ID: 23857473
[TBL] [Abstract][Full Text] [Related]
15. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
[TBL] [Abstract][Full Text] [Related]
16. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
Guillaume YC; Lethier L; André C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.
Aguilera DG; Das CM; Sinnappah-Kang ND; Joyce C; Taylor PH; Wen S; Hasselblatt M; Paulus W; Fuller G; Wolff JE; Gopalakrishnan V
J Neurooncol; 2009 Jul; 93(3):303-18. PubMed ID: 19148581
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs.
Jayasooriya RG; Choi YH; Hyun JW; Kim GY
Environ Toxicol Pharmacol; 2014 Nov; 38(3):959-67. PubMed ID: 25461556
[TBL] [Abstract][Full Text] [Related]
19. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
20. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]